We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00458419
Recruitment Status : Completed
First Posted : April 10, 2007
Last Update Posted : November 2, 2007
Information provided by:

Study Description
Brief Summary:

Endorphins are naturally occurring narcotic substances that are released when individuals perform exercise. The hypothesis of the study is that endorphins reduce the severity of breathlessness during exercise in patients with chronic obstructive pulmonary disease (COPD). The initial five visits include familiarization and validation of a computerized system for patients to report dyspnea and leg discomfort continuously during exercise testing.

At Visits 6 and 7 blood is drawn to measure serum endorphin levels pre-exercise, end exercise, and 30 minutes after exercise. Normal saline or naloxone is given intravenously 5 minutes prior to exercise in a double-blinded design. The primary outcome is the slope of oxygen consumption - dyspnea.

Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease Drug: naloxone versus placebo Drug: intravenous injection of normal saline or naloxone

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 17 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease
Study Start Date : September 2005
Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Placebo Comparator: A: naloxone; B: normal saline
Arm A: IV naloxone Arm B: IV normal saline
Drug: naloxone versus placebo
10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
Drug: intravenous injection of normal saline or naloxone
Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline

Outcome Measures

Primary Outcome Measures :
  1. Slope of oxygen consumption - dyspnea during treadmill exercise. [ Time Frame: throughout exercise ]

Secondary Outcome Measures :
  1. Exercise duration [ Time Frame: 10-14 minutes ]
  2. Peak ratings of breathlessness [ Time Frame: at end of exercsie - 10-15 minutes ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of COPD
  • Ability to exercise
  • Ability to computer mouse to provide ratings
  • > 10 pack-years smoking
  • Baseline dyspnea index < 9

Exclusion Criteria:

  • Clinically significant comorbidities
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00458419

United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756-0001
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Doanld A Mahler, MD Dartmouth-Hitchcock Medical Center
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00458419     History of Changes
Other Study ID Numbers: 17355
First Posted: April 10, 2007    Key Record Dates
Last Update Posted: November 2, 2007
Last Verified: October 2007

Keywords provided by Dartmouth-Hitchcock Medical Center:
dyspnea; leg discomfort; exercise duration

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Respiration Disorders
Signs and Symptoms, Respiratory
Signs and Symptoms
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action